CLAIMS

1. A crystalline form of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide, wherein said crystalline compound is the hydrochloride of said compound, the hydrobromide of said compound, the p-toluenesulfonate of said compound, the sulfate of said compound, the methanesulfonate of said compound or the ethanesulfonate of said compound, or the solvate of said salt.

2. A crystalline form of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide methanesulfonate or the solvate of said salt.

3. A crystalline form of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide ethanesulfonate or the solvate of said salt.

4. A crystalline form of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide methanesulfonate.

5. A crystalline form of the hydrate of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide methanesulfonate.

6. A crystalline form of the dimethyl sulfoxide solvate of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide methanesulfonate.

7. A crystalline form of the acetic acid solvate of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide methanesulfonate.

8. A crystalline form of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide ethanesulfonate.

9. A crystalline form of the dimethyl sulfoxide solvate of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide ethanesulfonate.

10. A crystalline form according to claim 4 (Form A) having

diffraction peaks at diffraction angles (2θ ± 0.2°) of 9.65° and 18.37° in a powder X-ray diffraction.

11. A crystalline form according to claim 4 (Form A) having peaks at chemical shifts of about 162.4 ppm, about 128.0 ppm, about 102.3 ppm and about 9.9 ppm in a ^{13}C Solid State Nuclear Magnetic Resonance spectrum.

12. A crystalline form according to claim 4 (Form A) having absorption bands at wavenumbers of 1161 ± 1 cm^{-1} and 1044 ± 1 cm^{-1} in an infrared absorption spectrum.

13. A crystalline form according to claim 4 (Form B) having diffraction peaks at diffraction angles (2θ ± 0.2°) of 5.72° and 13.84° in a powder X-ray diffraction.

14. A crystalline form according to claim 4 (Form B) having absorption bands at wavenumbers of 1068 ± 1 cm^{-1} and 918 ± 1 cm^{-1} in an infrared absorption spectrum.

15. A crystalline form according to claim 4 (Form C) having diffraction peaks at diffraction angles (2θ ± 0.2°) of 14.20° and 17.59° in a powder X-ray diffraction.

16. A crystalline form according to claim 4 (Form C) having peaks at chemical shifts of about 160.2 ppm, about 126.6 ppm, about 105.6 ppm and about 7.8 ppm in a ^{13}C Solid State Nuclear Magnetic Resonance spectrum.

17. A crystalline form according to claim 4 (Form C) having absorption bands at wavenumbers of 1324 ± 1 cm^{-1} and 579 ± 1 cm^{-1} in an infrared absorption spectrum.

18. A crystalline form according to claim 5 (Form F) having diffraction peaks at diffraction angles (2θ ± 0.2°) of 8.02° and 18.14° in a powder X-ray diffraction.

19. A crystalline form according to claim 7 (Form I) having diffraction peaks at diffraction angles (2θ ± 0.2°) of 9.36° and 12.40° in a powder X-ray diffraction.

20. A crystalline form according to claim 7 (Form I) having absorption bands at wavenumbers of 1750 ± 1 cm^{-1} and 1224 ± 1 cm^{-1} in an

infrared absorption spectrum.

21. A crystalline form according to claim 8 (Form α) having diffraction peaks at diffraction angles (2θ ± 0.2°) of 15.70° and 17.18° in a powder X-ray diffraction.

22. A crystalline form according to claim 8 (Form α) having absorption bands at wavenumbers of 1320 ± 1 cm^{-1} and 997 ± 1 cm^{-1} in an infrared absorption spectrum.

23. A crystalline form according to claim 8 (Form β) having diffraction peaks at diffraction angles (2θ ± 0.2°) of 6.48° and 9.58° in a powder X-ray diffraction.

24. A crystalline form according to claim 8 (Form β) having absorption bands at wavenumbers of 1281 ± 1 cm^{-1} and 985 ± 1 cm^{-1} in an infrared absorption spectrum.

25. A process for preparing a crystalline form of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide methanesulfonate (Form A), comprising a step of mixing 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide, a solvent and methanesulfonic acid to dissolve.

26. A process for preparing a crystalline form of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide methanesulfonate (Form A), comprising a step of mixing 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide, acetic acid and methanesulfonic acid to dissolve.

27. A process for preparing a crystalline form of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide methanesulfonate (Form B), comprising a step of drying a crystalline form of the acetic acid solvate of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide methanesulfonate (Form I) to remove acetic acid.

28. A process for preparing a crystalline form of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-

quinolinecarboxamide methanesulfonate (Form C), comprising a step of heating a crystalline form of the dimethyl sulfoxide solvate of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide methanesulfonate.

29. A process for preparing a crystalline form of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide methanesulfonate (Form C), comprising a step of mixing a crystalline form of the acetic acid solvate of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide methanesulfonate (Form I) and a solvent.

30. A process for preparing a crystalline form of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-methoxy-6-quinolinecarboxamide methanesulfonate (Form C), comprising a step of mixing 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide, acetic acid and methanesulfonic acid to dissolve.

31. A process for preparing a crystalline form of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide methanesulfonate (Form C), comprising a step of humidifying a crystalline form of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide methanesulfonate (Form B).

32. A process for preparing a crystalline form of the hydrate of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide methanesulfonate (Form F), comprising a step of mixing 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide, acetic acid and methanesulfonic acid to dissolve.

33. A process for preparing a crystalline form of the acetic acid solvate of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide methanesulfonate (Form I), comprising a step of mixing 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide, acetic acid and methanesulfonic acid to

dissolve.

34. A process for preparing a crystalline form of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide ethanesulfonate (Form α), comprising a step of mixing 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide, a solvent and ethanesulfonic acid to dissolve.

35. A process for preparing a crystalline form of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide ethanesulfonate (Form β), comprising a step of mixing a crystalline form of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide ethanesulfonate (Form α) and a solvent.

36. A process for preparing a crystalline form of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide ethanesulfonate (Form β), comprising a step of mixing 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide, acetic acid and ethanesulfonic acid to dissolve.

37. A pharmaceutical composition, comprising the crystalline form according to any one of claims 1 to 24.

38. A prophylactic or therapeutic agent for a disease for which angiogenesis inhibition is effective, comprising the crystalline form according to any one of claims 1 to 24.

39. An angiogenesis inhibitor, comprising the crystalline form according to any one of claims 1 to 24.

40. An anti-tumor agent, comprising the crystalline form according to any one of claims 1 to 24.

41. An anti-tumor agent according to claim 40, wherein the tumor is a pancreatic cancer, a gastric cancer, a colon cancer, a breast cancer, a prostrate cancer, a lung cancer, a renal cancer, a brain tumor, a blood cancer or an ovarian cancer.

42. A therapeutic agent for angioma, comprising the crystalline

form according to any one of claims 1 to 24.

43. A cancer metastasis inhibitor, comprising the crystalline form according to any one of claims 1 to 24.

44. A therapeutic agent for retinal neovascularization, comprising the crystalline form according to any one of claims 1 to 24.

45. A therapeutic agent for diabetic retinopathy, comprising the crystalline form according to any one of claims 1 to 24.

46. A therapeutic agent for an inflammatory disease, comprising the crystalline form according to any one of claims 1 to 24.

47. A therapeutic agent for an inflammatory disease according to claim 46, wherein the inflammatory disease is deformant arthritis, rheumatoid arthritis, psoriasis or delayed hypersensitivity reaction.

48. A therapeutic agent for atherosclerosis, comprising the crystalline form according to any one of claims 1 to 24.

49. A method for preventing or treating a disease for which angiogenesis inhibition is effective, comprising administering to a patient, a pharmacologically effective dose of the crystalline form according to any one of claims 1 to 24.

50. Use of the crystalline form according to any one of claims 1 to 24 for the manufacture of a prophylactic or therapeutic agent for a disease for which angiogenesis inhibition is effective.